CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 4.5%

CRISPR Therapeutics AG (NASDAQ:CRSP)’s stock price was up 4.5% during trading on Tuesday . The stock traded as high as $58.68 and last traded at $58.15. Approximately 391,733 shares traded hands during mid-day trading, a decline of 78% from the average daily volume of 1,814,702 shares. The stock had previously closed at $55.66.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on CRSP shares. Mizuho raised their price target on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. Wolfe Research initiated coverage on shares of CRISPR Therapeutics in a research note on Thursday, February 15th. They set a “peer perform” rating on the stock. Chardan Capital raised their price objective on shares of CRISPR Therapeutics from $110.00 to $112.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. Needham & Company LLC reiterated a “buy” rating and set a $90.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday, April 11th. Finally, Barclays raised their price objective on shares of CRISPR Therapeutics from $61.00 to $80.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 22nd. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, CRISPR Therapeutics currently has an average rating of “Hold” and a consensus target price of $76.29.

CRISPR Therapeutics Trading Up 2.7 %

The stock has a market cap of $4.85 billion, a P/E ratio of -29.01 and a beta of 1.76. The firm’s fifty day moving average is $72.54 and its 200 day moving average is $63.76.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Wednesday, February 21st. The company reported $1.10 EPS for the quarter, topping the consensus estimate of $0.15 by $0.95. The firm had revenue of $201.20 million during the quarter, compared to the consensus estimate of $148.72 million. The business’s revenue was up 3253.3% compared to the same quarter last year. During the same quarter last year, the business earned ($1.41) EPS. Research analysts forecast that CRISPR Therapeutics AG will post -6.24 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 19,582 shares of CRISPR Therapeutics stock in a transaction on Monday, April 15th. The shares were sold at an average price of $59.91, for a total value of $1,173,157.62. Following the transaction, the chief executive officer now owns 208,122 shares in the company, valued at approximately $12,468,589.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CFO Raju Prasad sold 3,524 shares of the business’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $72.69, for a total transaction of $256,159.56. Following the transaction, the chief financial officer now owns 6,476 shares in the company, valued at approximately $470,740.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Samarth Kulkarni sold 19,582 shares of the business’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the transaction, the chief executive officer now owns 208,122 shares in the company, valued at approximately $12,468,589.02. The disclosure for this sale can be found here. Insiders have sold 133,992 shares of company stock worth $9,157,835 in the last quarter. 4.10% of the stock is currently owned by company insiders.

Institutional Trading of CRISPR Therapeutics

Several institutional investors have recently made changes to their positions in the business. Signaturefd LLC boosted its position in shares of CRISPR Therapeutics by 12.5% during the 3rd quarter. Signaturefd LLC now owns 2,124 shares of the company’s stock valued at $96,000 after acquiring an additional 236 shares in the last quarter. Itau Unibanco Holding S.A. boosted its position in CRISPR Therapeutics by 10.8% in the third quarter. Itau Unibanco Holding S.A. now owns 2,521 shares of the company’s stock valued at $114,000 after buying an additional 245 shares in the last quarter. Spire Wealth Management boosted its position in CRISPR Therapeutics by 32.7% in the third quarter. Spire Wealth Management now owns 1,052 shares of the company’s stock valued at $48,000 after buying an additional 259 shares in the last quarter. CWM LLC boosted its position in CRISPR Therapeutics by 80.7% in the third quarter. CWM LLC now owns 582 shares of the company’s stock valued at $26,000 after buying an additional 260 shares in the last quarter. Finally, WealthPlan Investment Management LLC boosted its position in CRISPR Therapeutics by 3.1% in the fourth quarter. WealthPlan Investment Management LLC now owns 9,663 shares of the company’s stock valued at $605,000 after buying an additional 288 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.